Arrowhead Pharmaceuticals, Inc. Share Price
NASDAQ: ARWR | Large CapArrowhead Pharmaceuticals, Inc. Stock Performance
Arrowhead Pharmaceuticals, Inc. Share Price Today
As of 14 September 2026, Arrowhead Pharmaceuticals, Inc.'s share price is $82.89. The stock opened at $84.91, compared to its previous close of $82.78. During today's trading session, Arrowhead Pharmaceuticals, Inc.'s share price traded between $82.48 and $85.78, with an average price of $84.13. Over the past 52 weeks, the stock has recorded a high of $95.39 and a low of $27.95. In terms of performance, Arrowhead Pharmaceuticals, Inc.'s share price has risen by 32.20% over the last six months and is up 140.07% on a year-on-year basis.
Arrowhead Pharmaceuticals, Inc. Share Price Chart
Arrowhead Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Arrowhead Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Sep 2026 | $81.25 | $82.89 | -6.49% |
Aug 2026 | $84.81 | $88.65 | +4.74% |
Jul 2026 | $80.56 | $84.64 | +3.85% |
Jun 2026 | $75.95 | $81.50 | +4.54% |
May 2026 | $74.40 | $77.96 | +6.08% |
Apr 2026 | $63.35 | $73.49 | +17.20% |
Mar 2026 | $61.50 | $62.70 | -0.85% |
Feb 2026 | $68.70 | $63.24 | -8.76% |
Jan 2026 | $66.47 | $69.31 | +4.42% |
Dec 2025 | $53.89 | $66.38 | +26.01% |
Nov 2025 | $41.83 | $52.68 | +24.23% |
Oct 2025 | $34.64 | $42.41 | +22.81% |
ARWR Share Price FAQs
What is Arrowhead Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Arrowhead Pharmaceuticals, Inc. stock?
What is ARWR's market capitalisation today?
What is ARWR's net income for the last quarter?
What is the 5 year returns of ARWR?
What is the high & low stock price of ARWR today?
Can I buy ARWR shares in India?